Novocure
Updated: December 07, 2025
Asaf Danziger, CEO and William Doyle, Chairman
Country: Israel | Funding: $1B (+)
Founded: 2000
Website: https://www.novocure.com/
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
Founded: 2000
Website: https://www.novocure.com/
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
